Advertisement

EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation

Lauren P. McLaughlin, Rayne Rouce, Stephen Gottschalk, Vicky Torrano, George Carrum, Meng-Fen Wu, Fahmida Hoq, Bambi Grilley, Andrea M. Marcogliese, Patrick J. Hanley, Adrian P. Gee, Malcolm K. Brenner, Cliona M. Rooney, Helen E. Heslop and Catherine M. Bollard

Article Information

Citation 
vol. 132 no. 22 2351-2361
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted July 15, 2018
  • Accepted September 13, 2018
  • Published online November 29, 2018.

Article Versions


Contributors 
  • Lauren P. McLaughlin, 1Center for Cancer and Immunology Research, Children’s National Health System and George Washington University, Washington, DC;
  • Rayne Rouce, 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, and Texas Children's Hospital, Houston, TX; and
  • Stephen Gottschalk, 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, and Texas Children's Hospital, Houston, TX; and 3Dan L. Duncan Comprehensive Cancer Center, 4Department of Pediatrics,
  • Vicky Torrano, 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, and Texas Children's Hospital, Houston, TX; and
  • George Carrum, 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, and Texas Children's Hospital, Houston, TX; and 5Department of Immunology,
  • Meng-Fen Wu, 3Dan L. Duncan Comprehensive Cancer Center,
  • Fahmida Hoq, 1Center for Cancer and Immunology Research, Children’s National Health System and George Washington University, Washington, DC;
  • Bambi Grilley, 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, and Texas Children's Hospital, Houston, TX; and
  • Andrea M. Marcogliese, 6Department of Pathology,
  • Patrick J. Hanley, 1Center for Cancer and Immunology Research, Children’s National Health System and George Washington University, Washington, DC;
  • Adrian P. Gee, 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, and Texas Children's Hospital, Houston, TX; and 3Dan L. Duncan Comprehensive Cancer Center, 4Department of Pediatrics,
  • Malcolm K. Brenner, 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, and Texas Children's Hospital, Houston, TX; and 3Dan L. Duncan Comprehensive Cancer Center, 7Department of Medicine, and
  • Cliona M. Rooney, 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, and Texas Children's Hospital, Houston, TX; and 3Dan L. Duncan Comprehensive Cancer Center, 4Department of Pediatrics, 5Department of Immunology, 8Department of Virology, Baylor College of Medicine, Houston, TX
  • Helen E. Heslop, 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, and Texas Children's Hospital, Houston, TX; and 3Dan L. Duncan Comprehensive Cancer Center, 7Department of Medicine, and
  • Catherine M. Bollard, 1Center for Cancer and Immunology Research, Children’s National Health System and George Washington University, Washington, DC; 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, and Texas Children's Hospital, Houston, TX; and 3Dan L. Duncan Comprehensive Cancer Center, 4Department of Pediatrics, 5Department of Immunology, 6Department of Pathology,

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output